214 related articles for article (PubMed ID: 27105527)
1. Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src.
Perez M; Lucena-Cacace A; Marín-Gómez LM; Padillo-Ruiz J; Robles-Frias MJ; Saez C; Garcia-Carbonero R; Carnero A
Oncotarget; 2016 May; 7(22):33111-24. PubMed ID: 27105527
[TBL] [Abstract][Full Text] [Related]
2. Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress.
Kopetz S; Lesslie DP; Dallas NA; Park SI; Johnson M; Parikh NU; Kim MP; Abbruzzese JL; Ellis LM; Chandra J; Gallick GE
Cancer Res; 2009 May; 69(9):3842-9. PubMed ID: 19383922
[TBL] [Abstract][Full Text] [Related]
3. Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells.
Shi M; Lou B; Ji J; Shi H; Zhou C; Yu Y; Liu B; Zhu Z; Zhang J
Cancer Chemother Pharmacol; 2013 Jul; 72(1):35-44. PubMed ID: 23712327
[TBL] [Abstract][Full Text] [Related]
4. Targeting SRC in mucinous ovarian carcinoma.
Matsuo K; Nishimura M; Bottsford-Miller JN; Huang J; Komurov K; Armaiz-Pena GN; Shahzad MM; Stone RL; Roh JW; Sanguino AM; Lu C; Im DD; Rosenshien NB; Sakakibara A; Nagano T; Yamasaki M; Enomoto T; Kimura T; Ram PT; Schmeler KM; Gallick GE; Wong KK; Frumovitz M; Sood AK
Clin Cancer Res; 2011 Aug; 17(16):5367-78. PubMed ID: 21737505
[TBL] [Abstract][Full Text] [Related]
5. HSP90 inhibition downregulates thymidylate synthase and sensitizes colorectal cancer cell lines to the effect of 5FU-based chemotherapy.
Nagaraju GP; Alese OB; Landry J; Diaz R; El-Rayes BF
Oncotarget; 2014 Oct; 5(20):9980-91. PubMed ID: 25296971
[TBL] [Abstract][Full Text] [Related]
6. The role of lysyl oxidase in SRC-dependent proliferation and metastasis of colorectal cancer.
Baker AM; Cox TR; Bird D; Lang G; Murray GI; Sun XF; Southall SM; Wilson JR; Erler JT
J Natl Cancer Inst; 2011 Mar; 103(5):407-24. PubMed ID: 21282564
[TBL] [Abstract][Full Text] [Related]
7. Activation of the mTOR Pathway by Oxaliplatin in the Treatment of Colorectal Cancer Liver Metastasis.
Lu M; Zessin AS; Glover W; Hsu DS
PLoS One; 2017; 12(1):e0169439. PubMed ID: 28060954
[TBL] [Abstract][Full Text] [Related]
8. Src family kinase inhibitor Saracatinib (AZD0530) impairs oxaliplatin uptake in colorectal cancer cells and blocks organic cation transporters.
Morrow CJ; Ghattas M; Smith C; Bönisch H; Bryce RA; Hickinson DM; Green TP; Dive C
Cancer Res; 2010 Jul; 70(14):5931-41. PubMed ID: 20551056
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts.
Nukatsuka M; Nakagawa F; Takechi T
Anticancer Res; 2015 Sep; 35(9):4605-15. PubMed ID: 26254349
[TBL] [Abstract][Full Text] [Related]
10. Ursolic acid synergistically enhances the therapeutic effects of oxaliplatin in colorectal cancer.
Shan J; Xuan Y; Zhang Q; Zhu C; Liu Z; Zhang S
Protein Cell; 2016 Aug; 7(8):571-85. PubMed ID: 27472952
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effect of pyrrolo-1,5-benzoxazepine-15 and its synergistic effect with Oxaliplatin and 5-FU in colorectal cancer cells.
Fiore D; Proto MC; Pisanti S; Picardi P; Pagano Zottola AC; Butini S; Gemma S; Casagni A; Laezza C; Vitale M; Ligresti A; Di Marzo V; Zisterer DM; Nathwani S; Williams DC; Campiani G; Gazzerro P; Bifulco M
Cancer Biol Ther; 2016 Aug; 17(8):849-58. PubMed ID: 26392056
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the efficacy of dasatinib, a Src/Abl inhibitor, in colorectal cancer cell lines and explant mouse model.
Scott AJ; Song EK; Bagby S; Purkey A; McCarter M; Gajdos C; Quackenbush KS; Cross B; Pitts TM; Tan AC; Eckhardt SG; Fenton H; Arcaroli J; Messersmith WA
PLoS One; 2017; 12(11):e0187173. PubMed ID: 29091939
[TBL] [Abstract][Full Text] [Related]
13. Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab.
Prewett M; Deevi DS; Bassi R; Fan F; Ellis LM; Hicklin DJ; Tonra JR
Clin Cancer Res; 2007 Dec; 13(24):7432-40. PubMed ID: 18094427
[TBL] [Abstract][Full Text] [Related]
14. Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer.
Schmieder R; Hoffmann J; Becker M; Bhargava A; Müller T; Kahmann N; Ellinghaus P; Adams R; Rosenthal A; Thierauch KH; Scholz A; Wilhelm SM; Zopf D
Int J Cancer; 2014 Sep; 135(6):1487-96. PubMed ID: 24347491
[TBL] [Abstract][Full Text] [Related]
15. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.
Culy CR; Clemett D; Wiseman LR
Drugs; 2000 Oct; 60(4):895-924. PubMed ID: 11085200
[TBL] [Abstract][Full Text] [Related]
16. The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling.
Booth L; Roberts JL; Tavallai M; Webb T; Leon D; Chen J; McGuire WP; Poklepovic A; Dent P
Oncotarget; 2016 Apr; 7(15):19620-30. PubMed ID: 26934000
[TBL] [Abstract][Full Text] [Related]
17. Global phosphotyrosine proteomics identifies PKCδ as a marker of responsiveness to Src inhibition in colorectal cancer.
McKinley ET; Liu H; McDonald WH; Luo W; Zhao P; Coffey RJ; Hanks SK; Manning HC
PLoS One; 2013; 8(11):e80207. PubMed ID: 24260357
[TBL] [Abstract][Full Text] [Related]
18. The synergistic effect of recombinant human endostatin (YH-16) combined with oxaliplatin on human colorectal carcinoma.
Zhang DW; Li HL; Yao Q; Yang WL; Wang HL; Zhai DX; Zhou ZH
J Int Med Res; 2010; 38(1):111-26. PubMed ID: 20233520
[TBL] [Abstract][Full Text] [Related]
19. Ursolic acid enhances the therapeutic effects of oxaliplatin in colorectal cancer by inhibition of drug resistance.
Zhang Y; Huang L; Shi H; Chen H; Tao J; Shen R; Wang T
Cancer Sci; 2018 Jan; 109(1):94-102. PubMed ID: 29034540
[TBL] [Abstract][Full Text] [Related]
20. Severe liver dysfunction and safe use of 5-fluorouracil leucovorin and oxaliplatin in one patient with metastatic colorectal carcinoma.
Tural D; Akar E; Öztürk MA; Yıldız Ö; Turna H; Serdengeçti S
J Cancer Res Ther; 2014; 10(3):745-8. PubMed ID: 25313774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
